Kenvue stock rallied on Tuesday off a record low, after a White House press conference didn’t offer fresh evidence that could be used by plaintiffs to sue the maker of Tylenol for its alleged link to autism.

Families appealing the dismissal of their lawsuits alleging that Kenvue's Tylenol or generic versions of the pain-relief medication caused their children's autism are asking an appeals court to consider President Donald Trump's new advice that pregnant women avoid the pain killer as it decides whether to revive their lawsuits.

The White House is reportedly planning to link Tylenol use during pregnancy to autism. The news pushed Kenvue stock down 8%.

Kenvue's profitability, with gross margins above 58% and EBITDA margins over 23%, provides resilience against legal and headline risks. Learn more about KVUE stock here.

The post shared on social media was authentic, but Tylenol maker Kenvue said the response was "incomplete" and didn't reflect its "full guidance."

A newly resurfaced tweet from Tylenol, warning pregnant women to avoid "any of our products," has gone viral in MAGA social media circles days after President Donald Trump announced it may be linked to autism.

Kenvue, a two-year-old spinoff from Johnson & Johnson, is confronting a public-relations nightmare as President Trump and others suggest unproven links between the pain reliever and autism.

Trump and Heath and Human Service Secretary Robert F. Kennedy Jr. urged pregnant women on Monday to avoid taking Tylenol, and its active ingredient acetaminophen, despite limited evidence finding an association of increased autism in children. Trump emphasized to “fight like hell” to avoid taking the painkiller.